Is chemoimmunotherapy in the relapsed/refractory setting still useful in CLL?
Outcomes of CLL patients following treatment with a covalent BTK and BCL2 inhibitor
Toby Eyre • 15 Jun 2022
Results of QuANTUM-First: quizartinib vs placebo plus intensive chemotherapy in FLT3-ITD+ AML
Harry Erba • 12 Jun 2022